AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
THIS AMENDMENT, dated as of September 29, 2011, between AxoGen Corporation, a Florida corporation (“AxoGen”), and John P. Engels (“Employee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Florida
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and effective as of the date first written below, by and between AXOGEN CORPORATION, a Florida corporation (“AXOGEN”), and Karen L. Zaderej (“Employee”).
PATENT LICENSE AGREEMENTPatent License Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Texas
This Agreement is between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, and Axogen Corporation., a corporation having a principal place of business located at 2153 SE Hawthorne Road, Gainesville, FL, 32641 (“Licensee”).
DISTRIBUTION AGREEMENTDistribution Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Distribution Agreement (“Agreement”) is entered into this 27th day of August, 2008 (“Effective Date”), by and between Cook Biotech Incorporated, an Indiana corporation having a place of business at 1425 Innovation Place, West Lafayette, Indiana 47906 (“Cook”), and AxoGen, Inc, a Delaware corporation having a place of business at 13859 Progress Blvd, Alachua, FL, 32615 (“Distributor”).
Sid Martin Biotechnology Development Institute INCUBATOR LICENSE AGREEMENTIncubator License Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Florida
THIS AGREEMENT, made this 26th day of September, 2006, between AxoGen Inc., (“Licensee), and the University of Florida Research Foundation, Inc., a Florida not-for-profit corporation (“UFRF”) in Gainesville, Florida.
AXOGEN AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (“Agreement”) consists of this signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the “Effective Date” shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the “Original Agreement”).
AMENDED AND RESTATED STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMSStandard Exclusive License Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
This Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms (this “Agreement”) is made and entered into as of February 21, 2006 (the “Amended Agreement Date”), by and between the University of Florida Research Foundation, Inc. (hereinafter called “UFRF”), a nonstock, nonprofit Florida corporation, and Axogen Corporation (hereinafter called “Licensee”), a corporation organized and existing under the laws of Florida. This Agreement amends and restates that certain Standard License Agreement with Sublicensing Terms between UFRF and Licensee dated June 5, 2003. The Effective Date of the Agreement, as amended and restated here, remains June 5, 2003.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Maryland
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of September 30, 2011 (the “Closing Date”) by and among MIDCAP FINANCIAL SBIC, LP, a Delaware limited partnership, (“MidCap”), as administrative agent (“Agent”), the Lenders listed on Schedule 1 hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), and AXOGEN, INC. (f/k/a LecTec Corporation), a Minnesota corporation (“AxoGen Inc”), and AXOGEN CORPORATION, a Delaware corporation (“AxoGen Corp”; together with AxoGen Inc, either individually or collectively as the context may require, as “Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay Lenders. The parties agree as follows:
SECOND AMENDMENT TO AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
THIS SECOND AMENDMENT (“Second Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, as amended on June 27, 2008 (“Amendment”), entered into by and among LifeNet Health (“LifeNet”) and AxoGen Corporation (the “Agreement”), is entered into between the parties on August 9, 2011 (“Effective Date”).
